𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Incidence of oral carcinoma in patients with leukoplakia of the oral mucosa

✍ Scribed by Dr. Jerzy Einhorn; Jan Wersäll


Publisher
John Wiley and Sons
Year
1967
Tongue
English
Weight
394 KB
Volume
20
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Cellular manifestations of human papillo
✍ Pillai, M. Radhakrishna; Phanidhara, A.; Kesari, A. Lakshmi; Nair, Pradip; Nair, 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 394 KB 👁 1 views

## Background and objectives: Human papillomavirus infection has been suggested to play a role in the development of epithelial carcinomas, particularly those of the uterine cervix. less information is available on the role of the virus in oral lesions. it has been proposed that the viral oncoprote

OVEREXPRESSION OF p53 IN NORMAL ORAL MUC
✍ OGDEN, GRAHAM R.; CHISHOLM, DERRICK M.; MORRIS, ARTHUR M.; STEVENSON, J. HOWARD 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 261 KB 👁 1 views

Recent reports of p53 positivity in the normal mucosa of some head and neck cancer patients have been taken as evidence for field cancerization and hence a likelihood of the development of further tumours, yet few papers report the clinical significance of this finding through long-term follow-up. T

Phase II study of the oral cyclophospham
✍ Catherine Maulard-Durdux; Bertrand Dufour; Christophe Hennequin; Y. Chrétien; Sy 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB 👁 2 views

## BACKGROUND. Hormonotherapy temporarily controls symptoms in 80% of patients with metastatic prostate carcinoma. Once progression occurs, no consensus exists on further therapy. Oral etoposide (vp-16) has shown clinical efficacy in advanced small cell lung carcinoma, breast cancer, germ cell tum

Pharmacokinetics of oral methotrexate in
✍ Judith M. Dalrymple; Lisa K. Stamp; John L. O'Donnell; Peter T. Chapman; Mei Zha 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 282 KB 👁 2 views

## Abstract ## Objective There is evidence supporting a therapeutic range for methotrexate polyglutamate (MTXGlu) concentrations in the treatment of rheumatoid arthritis (RA). Knowledge of the pharmacokinetics of MTXGlu~1–5~ is required for optimal timing of blood sampling. The aim of this study w